What are the differences between Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Monoclonal Gammopathy of Renal Significance (MGRS) in adults over 60?

Understanding and Differentiating Monoclonal Gammopathies

Core Concept: The Spectrum of Plasma Cell Disorders

The fundamental distinction between MGUS, Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM) rests entirely on three factors: the burden of disease (M-protein level and bone marrow plasma cell percentage), the presence of clonality, and most critically—whether end-organ damage exists. 1

The Progression Continuum

These conditions represent a biological continuum where nearly all patients with MM evolve from MGUS, sometimes passing through an intermediate SMM stage 1:

• MGUS progresses to malignancy at 1% per year (constant lifelong risk) 1
• SMM progresses at 10% per year for the first 5 years, then 3% per year for the next 5 years, then 1.5% per year thereafter 1

---

Diagnostic Criteria: The Three-Tier Classification

MGUS (Monoclonal Gammopathy of Undetermined Significance)

All three criteria must be met 1:

1. Serum monoclonal protein <3 g/dL 1
2. Clonal bone marrow plasma cells <10% 1
3. Absence of end-organ damage (no CRAB criteria) 1

Key point: MGUS is a benign precursor condition found in 3.2% of adults over 50 years and 5.3% of those over 70 years 1. The median age at diagnosis is 65-70 years 1.

Smoldering Multiple Myeloma (SMM)

Both criteria must be met 1:

1. Serum monoclonal protein (IgG or IgA) ≥3 g/dL and/or clonal bone marrow plasma cells ≥10% 1
2. Absence of end-organ damage (no CRAB criteria) 1

Critical distinction: SMM represents 10-15% of all MM cases and has significantly higher progression risk than MGUS 1.

Multiple Myeloma (MM)

All criteria must be met 1:

1. Clonal bone marrow plasma cells ≥10% or biopsy-proven plasmacytoma 1
2. Presence of serum and/or urinary monoclonal protein (except non-secretory MM) 1
3. Evidence of end-organ damage attributable to the plasma cell disorder 1

---

The CRAB Criteria: Defining End-Organ Damage

The presence of ANY CRAB criterion attributable to the plasma cell disorder defines symptomatic MM requiring immediate treatment 1:

• C = Calcium elevation: Serum calcium >11.5 mg/dL 1
• R = Renal insufficiency: Serum creatinine >1.73 mmol/L (>2 mg/dL) or creatinine clearance <40 mL/min 1
• A = Anemia: Hemoglobin ≥2 g/dL below lower limit of normal or <10 g/dL (normochromic, normocytic) 1
• B = Bone lesions: Lytic lesions, severe osteopenia, or pathologic fractures 1

Critical Pitfalls in Applying CRAB Criteria

You must exclude alternative causes before attributing findings to the plasma cell disorder 1:

• Renal insufficiency: Rule out diabetes, hypertension, or non-selective proteinuria from other causes 1
• Anemia: Exclude iron, B12, or folate deficiency; anemia of chronic disease; or myelodysplastic syndrome 1
• Bone lesions: Long-standing osteoporosis with gradual progression suggests benign disease, while sudden onset indicates active MM 1
• Hypercalcemia: Consider hyperparathyroidism, especially if stable and lytic lesions are absent 1

---

Monoclonal Gammopathy of Renal Significance (MGRS)

MGRS is a distinct entity where a monoclonal protein causes kidney damage in patients who otherwise meet MGUS criteria 2, 3:

• Definition: Kidney disorders caused by monoclonal protein from a small plasma cell or B-cell clone that does NOT meet criteria for MM or other B-cell malignancies 2, 3
• Underlying disorder: Generally consistent with MGUS by hematologic criteria 2, 3
• Key difference from MGUS: The monoclonal protein causes significant renal injury requiring treatment, despite not meeting MM criteria 2, 3

MGRS Manifestations

The spectrum includes 2, 3:

• AL amyloidosis (most common)
• Proliferative glomerulonephritis with monoclonal Ig deposits
• C3 glomerulopathy with monoclonal gammopathy
• Light chain deposition disease
• Various tubulopathies and vascular involvement

Critical management principle: MGRS requires clone-directed chemotherapy to suppress monoclonal protein production, which can stop or reverse kidney disease 2, 3. This distinguishes it from MGUS, where treatment is never indicated outside clinical trials 4, 5.

---

Diagnostic Workup: A Systematic Approach

Initial Laboratory Testing (Required for All Suspected Cases)

Every patient requires this baseline evaluation 1, 4:

1. Serum protein electrophoresis (SPEP) to detect and quantify M-protein 1, 4
2. Serum immunofixation electrophoresis (SIFE) to characterize heavy and light chains 1, 4
3. Quantitative immunoglobulins (IgG, IgA, IgM) 1, 4
4. Serum free light chain (FLC) assay with kappa/lambda ratio 1, 4
5. Complete blood count to assess for anemia 1, 4
6. Serum calcium and creatinine to detect end-organ damage 1, 4
7. 24-hour urine collection for protein electrophoresis and immunofixation 1, 4

Common pitfall: Missing light chain-only disease by relying solely on SPEP without immunofixation 6. Always perform immunofixation even when SPEP appears normal 6.

Bone Marrow Evaluation

Indications vary by suspected diagnosis 1, 4:

• MGUS (low-risk): Bone marrow biopsy NOT routinely indicated 4
• MGUS (intermediate/high-risk): Bone marrow aspirate and biopsy recommended at baseline to exclude underlying malignancy 4
• SMM and MM: Bone marrow examination ALWAYS required 1

The bone marrow sample should be used for 1:

• Plasma cell percentage and morphology
• Cytogenetics and FISH studies
• Immunophenotyping and molecular investigations

Imaging Studies

Skeletal survey is the standard for detecting lytic lesions 1:

• Required views: Spine, pelvis, skull, humeri, femurs 1
• MRI or CT: Indicated for symptomatic sites even if skeletal survey is negative 1
• MRI of spine/pelvis: Provides greater detail and is recommended when spinal cord compression is suspected 1

For SMM specifically: MRI of spine and pelvis can detect occult lesions and predict progression 6.

---

Risk Stratification: Predicting Progression

MGUS Risk Stratification

Three independent risk factors determine progression risk 1:

1. M-protein size: ≥1.5 g/dL (abnormal) vs <1.5 g/dL (normal)
2. Immunoglobulin type: Non-IgG (IgA or IgM) vs IgG
3. Free light chain ratio: Abnormal (outside 0.26-1.65) vs normal

Risk categories and 20-year progression rates 1:

• Low-risk (0 factors): 2% absolute risk
• Low-intermediate (1 factor): 10% relative risk
• High-intermediate (2 factors): 18% relative risk
• High-risk (3 factors): 27% relative risk

SMM Risk Stratification

Three risk factors predict early progression 1:

1. Abnormal FLC ratio (outside normal range)
2. Bone marrow plasma cells ≥10%
3. Serum M-protein ≥3 g/dL

5-year progression rates 1:

• 1 risk factor: 25% (median time to progression: 10 years)
• 2 risk factors: 51% (median time to progression: 5.1 years)
• 3 risk factors: 76% (median time to progression: 1.9 years)

---

Monitoring Strategies: Risk-Adapted Surveillance

MGUS Monitoring

Low-risk MGUS 1, 4, 5:

• Repeat SPEP at 6 months after diagnosis
• If stable, follow every 2-3 years for life or when symptoms arise
• Rationale: Only 2% lifetime risk of progression justifies less intensive monitoring

Intermediate/High-risk MGUS 1, 4, 5:

• Follow-up with SPEP and CBC at 6 months
• Then annually for life
• Consider bone marrow biopsy at baseline

SMM Monitoring

All SMM patients require closer surveillance 1:

• Testing 2-3 months after initial recognition
• If stable, follow every 4-6 months for 1 year
• If still stable, follow every 6-12 months thereafter

Critical point: SMM has 10% annual progression risk in first 5 years, warranting closer surveillance than MGUS 5.

---

Treatment Principles: When to Intervene

MGUS: Observation Only

MGUS patients should NEVER receive treatment outside clinical trials 5. The fundamental principle is that MGUS is an asymptomatic precursor with only 1% annual progression risk, and no therapy has demonstrated benefit in preventing progression 5.

SMM: Observation Remains Standard

Immediate treatment is NOT recommended for asymptomatic myeloma 1. Current standard is observation with risk-adapted monitoring 1.

Multiple Myeloma: Immediate Treatment Required

Treatment should be initiated in ALL patients with active myeloma fulfilling CRAB criteria 1. Symptomatic MM demands immediate therapy—never observation 5.

MGRS: Clone-Directed Therapy

Unlike MGUS, MGRS requires treatment to suppress monoclonal protein production 2, 3. Clone-directed chemotherapy, potentially including autologous stem cell transplantation in eligible patients, often results in improved renal outcomes 2.

---

Common Diagnostic Pitfalls to Avoid

1. Failing to perform immunofixation when SPEP is negative or equivocal 4, 6—this misses light chain-only disease

2. Discontinuing follow-up after stability 4—progression risk continues lifelong, even in low-risk MGUS

3. Attributing CRAB findings to the plasma cell disorder without excluding alternative causes 1—elderly patients often have comorbidities mimicking MM

4. Not recognizing MGRS 2, 3—kidney damage from monoclonal protein requires treatment despite meeting MGUS criteria hematologically

5. Treating MGUS outside clinical trials 4, 5—no benefit has been demonstrated and exposes patients to unnecessary toxicity

6. Confusing SMM with MGUS 5—SMM has 10-fold higher progression risk in first 5 years and requires closer monitoring

7. Missing IgA or IgM MGUS higher risk 6—these subtypes have higher progression rates than IgG MGUS